LEXINGTON, Mass.--(BUSINESS WIRE)--
Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, today announced three poster presentations at the American Glaucoma Society 2017 Annual Meeting to be held March 2-5 in Coronado, CA. The presentation details are as follows:
-
Incidence of Hyperemia in the Trabodenoson Monotherapy Clinical
Development Program Through Phase 2
Poster #: 87
Authors: C Rich, LJ Katz, C Murray, N Dgetluck, and R Baumgartner
Date: Friday, March 3, 2017
Time: 7:00am to 8:00am PST
-
Improved Function of Retinal Ganglion Cells by Topically
Administered Trabodenoson in a Rat Model of Optic Nerve Crush Injury
Poster #: 96
Authors: A Brockman, D Albers, J Tsai, C Rich, R Baumgartner, and W McVicar
Date: Friday, March 3, 2017
Time: 7:00am to 8:00am PST
-
Further Elucidation of the Mechanism of Action of Trabodenoson
Using Validated 3D-Human Trabecular Meshwork Constructs
Poster #: 140
Authors: D Albers, R Noecker, A Unser, F Ahmed, K Torrejon, R Baumgartner, and W McVicar
Date: Saturday, March 4, 2017
Time: 7:00am to 8:00am PST
Inotek will have an exhibition booth set up at #T27.
About Inotek Pharmaceuticals Corporation
Inotek
Pharmaceuticals is a clinical-stage biopharmaceutical company focused on
the discovery, development and commercialization of therapies for
glaucoma and other eye diseases. The Company’s lead product candidate, trabodenoson,
is a first-in-class selective adenosine mimetic currently in Phase 3
development. Trabodenoson was developed in Inotek’s laboratories
and is designed to restore the eye’s natural pressure control mechanism.
Additionally, the Company is evaluating the potential for selective
adenosine mimetics to address optic neuropathies and other degenerative
retinal diseases. For more information, please visit www.inotekpharma.com.
The inclusion of our website address here and elsewhere in this press
release does not include or incorporate by reference the information on
our website into this press release.
Forward-Looking Statements
This press release contains
forward-looking statements, which are subject to substantial risks,
uncertainties and assumptions. You should not place reliance on these
statements often include words such as "believe," "expect,"
"anticipate," "intend," "plan," "estimate," "seek," "will," "may" or
similar expressions. Although the Company believes that the expectations
reflected in the forward-looking statements are reasonable, the Company
cannot guarantee such outcomes. Accordingly, you should not place undue
reliance on these forward-looking statements. All such statements speak
only as of the date made, and the Company undertakes no obligation to
update or revise publicly any forward-looking statements, whether as a
result of new information, future events or otherwise.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170224005032/en/
